Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators

Author(s): Stefanie Rauscher, Richard Greil, Roland Geisberger*

Journal Name: Current Cancer Drug Targets

Volume 21 , Issue 4 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Cancer drug resistance is a major problem for cancer therapy. While many drugs can be effective in first-line treatments, cancer cells can become resistant due to genetic (mutations and chromosomal aberrations) but also epigenetic changes. Hence, many research studies addressed epigenetic drugs in circumventing resistance to conventional therapeutics in different tumor entities and in increasing the efficiency of immune checkpoint therapies. Furthermore, repositioning of already approved drugs in combination with epigenetic modifiers could potentiate their efficacy and thus could be an attractive strategy for cancer treatment. Summarizing, we recapitulate current data on epigenetic drugs and their targets in modulating sensitivity towards conventional and immune therapies, providing evidence that altering expression profiles by epigenetic modifiers holds great potential to improve the clinical outcome of cancer patients.

Keywords: Cancer drug resistance, epigenetic drugs, DNA methylation, histone modification, re-sensitizing, combinatorial treatments.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 07 January, 2021
Page: [353 - 359]
Pages: 7
DOI: 10.2174/1568009620666210108102723

Article Metrics

PDF: 72